(Bloomberg) -- Demand has grown so fervent for corporate bonds that investors are once again willing to finance big mergers and acquisitions — something they hesitated to do for much of last year.Most Read from BloombergBYD’s New $233,450 EV Supercar to Rival Ferrari, LamborghiniZelenskiy Says 31,000 Troops Killed as Ukraine Seeks US Aid Decision Within MonthNorwegian Cruise Ship Halted at Mauritius Due to OutbreakJack Ma-Backed Ant Outbids Citadel Securities for Credit Suisse’s China JVRisk Mod
European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.
(Bloomberg) -- Pharmaceutical giant AbbVie Inc. sold $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings. Most Read from BloombergNvidia Rises Most in About Nine Months as AI Drives SalesT-Bills Without Tax Bills? This Fund Says It Cracked the CodeStocks Rally as AI Craze Sweeps Across the World: Markets WrapAT&T Outage Triggered by Company Work on N